These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 26113018)

  • 21. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.
    Shahin MH; Cavallari LH; Perera MA; Khalifa SI; Misher A; Langaee T; Patel S; Perry K; Meltzer DO; McLeod HL; Johnson JA
    Thromb Haemost; 2013 Jun; 109(6):1045-50. PubMed ID: 23571513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose.
    Cavalli M; Pan G; Nord H; Eriksson N; Wadelius C; Wadelius M
    Pharmacogenomics; 2016 Aug; 17(12):1305-14. PubMed ID: 26847243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common VKORC1 and GGCX polymorphisms associated with warfarin dose.
    Wadelius M; Chen LY; Downes K; Ghori J; Hunt S; Eriksson N; Wallerman O; Melhus H; Wadelius C; Bentley D; Deloukas P
    Pharmacogenomics J; 2005; 5(4):262-70. PubMed ID: 15883587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose.
    Rieder MJ; Reiner AP; Rettie AE
    J Thromb Haemost; 2007 Nov; 5(11):2227-34. PubMed ID: 17764537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.
    Sominsky S; Korostishevsky M; Kurnik D; Aklillu E; Cohen Y; Ken-Dror G; Loebstein R; Halkin H; Gak E
    J Appl Genet; 2014 May; 55(2):163-71. PubMed ID: 24425227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PGWD: Integrating Personal Genome for Warfarin Dosing.
    Pan Y; Cheng R; Li Z; Zhao Y; He J
    Interdiscip Sci; 2016 Mar; 8(1):23-7. PubMed ID: 26267707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.
    Lewis BC; Nair PC; Heran SS; Somogyi AA; Bowden JJ; Doogue MP; Miners JO
    Pharmacogenet Genomics; 2016 Jan; 26(1):44-50. PubMed ID: 26513304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gamma-glutamyl carboxylase and its influence on warfarin dose.
    King CR; Deych E; Milligan P; Eby C; Lenzini P; Grice G; Porche-Sorbet RM; Ridker PM; Gage BF
    Thromb Haemost; 2010 Oct; 104(4):750-4. PubMed ID: 20694283
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Mg G; M H; A S
    Br J Biomed Sci; 2019 Jul; 76(3):150-152. PubMed ID: 30907254
    [No Abstract]   [Full Text] [Related]  

  • 30. Association between four microRNA binding site-related polymorphisms and the risk of warfarin-induced bleeding complications.
    Hosseindokht M; Boroumand M; Salehi R; Mandegary A; Hajhosseini Talasaz A; Pourgholi L; Zare H; Ziaee S; Sharifi M
    EXCLI J; 2019; 18():287-299. PubMed ID: 31338002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common VKORC1 variants are not associated with arterial or venous thrombosis.
    Hindorff LA; Heckbert SR; Smith N; Marciante KD; Psaty BM
    J Thromb Haemost; 2007 Oct; 5(10):2025-7. PubMed ID: 17883699
    [No Abstract]   [Full Text] [Related]  

  • 32. Epigenetics and MicroRNAs in Pharmacogenetics.
    Zanger UM; Klein K; Kugler N; Petrikat T; Ryu CS
    Adv Pharmacol; 2018; 83():33-64. PubMed ID: 29801581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Genetic Variability in Selected Genes in Patients With Deep Vein Thrombosis and Platelet Hyperaggregability.
    Sokol J; Skerenova M; Ivankova J; Simurda T; Stasko J
    Clin Appl Thromb Hemost; 2018 Oct; 24(7):1027-1032. PubMed ID: 29865896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of
    Al-Eitan LN; Almasri AY; Khasawneh RH; Alghamdi MA
    J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32916786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular pharmacogenetics in the SNP era.
    Mooser V; Waterworth DM; Isenhour T; Middleton L
    J Thromb Haemost; 2003 Jul; 1(7):1398-402. PubMed ID: 12871273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variants in
    Alghamdi MA; Al-Eitan L; Alkhatib R; Al-Assi A; Almasri A; Aljamal H; Aman H; Khasawneh R
    Int J Gen Med; 2021; 14():1093-1100. PubMed ID: 33790638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease.
    Al-Eitan LN; Elsaqa BZ; Almasri AY; Aman HA; Khasawneh RH; Alghamdi MA
    Pharmgenomics Pers Med; 2020; 13():619-632. PubMed ID: 33235484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin pharmacogenetics: challenges and opportunities for clinical translation.
    Limdi NA
    Front Pharmacol; 2012; 3():183. PubMed ID: 23133417
    [No Abstract]   [Full Text] [Related]  

  • 39. Warfarin pharmacogenetics: How close are we to clinical practice?
    Gaikwad T; Shetty S; Ghosh K
    Indian J Hum Genet; 2013 Jul; 19(3):277-8. PubMed ID: 24339537
    [No Abstract]   [Full Text] [Related]  

  • 40. Relative Expression of PBMC MicroRNA-133a Analysis in Patients Receiving Warfarin After Mechanical Heart Valve Replacement.
    Kabiri Rad H; Mazaheri M; Dehghani Firozabadi A
    Avicenna J Med Biotechnol; 2018; 10(1):29-33. PubMed ID: 29296264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.